A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2017
At a glance
- Drugs TAK 063 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 04 Nov 2017 Results published in the Drugs in R and D
- 12 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2013 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.